Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Accounts Payables (2016 - 2025)

Avalo Therapeutics (AVTX) has disclosed Accounts Payables for 12 consecutive years, with $474000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Accounts Payables fell 73.83% year-over-year to $474000.0, compared with a TTM value of $474000.0 through Sep 2025, down 73.83%, and an annual FY2024 reading of $283000.0, down 36.55% over the prior year.
  • Accounts Payables was $474000.0 for Q3 2025 at Avalo Therapeutics, down from $2.4 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $11.9 million in Q1 2021 and bottomed at $283000.0 in Q4 2024.
  • Average Accounts Payables over 5 years is $2.5 million, with a median of $1.8 million recorded in 2024.
  • The sharpest move saw Accounts Payables surged 337.01% in 2021, then plummeted 84.52% in 2023.
  • Year by year, Accounts Payables stood at $3.4 million in 2021, then decreased by 14.46% to $2.9 million in 2022, then crashed by 84.52% to $446000.0 in 2023, then plummeted by 36.55% to $283000.0 in 2024, then skyrocketed by 67.49% to $474000.0 in 2025.
  • Business Quant data shows Accounts Payables for AVTX at $474000.0 in Q3 2025, $2.4 million in Q2 2025, and $681000.0 in Q1 2025.